Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a ...

Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO ...

Amgen (NASDAQ:AMGN) shares fell 4.7% to $416.88 in premarket trading as investors assessed the implications of a Phase III trial result from Novartis involving an experimental Lp (a)-lowering ...

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...

Amgen (NASDAQ:AMGN) reported stronger-than-expected fourth-quarter results, posting solid revenue growth and upbeat guidance for 2026, which helped lift its shares slightly in premarket trading on ...

Amgen raised full-year 2026 revenue and EPS guidance, signaling improved confidence. Find out why AMGN stock is upgraded to ...

Amgen is getting the ball rolling on a far-reaching new partnership that’s set to boost its profile in its hometown of Greater Los Angeles. The Big Biotech has signed on as the official biotech ...

According to Amgen, DeLLphi-305 is the first Phase 3 study to include a Bispecific T-cell Engager (BiTE) therapy to demonstrate an overall survival benefit in the first-line maintenance setting for ES ...

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of $5.26 per share. Earnings rose 21% year over year as higher revenues were ...

Amgen (AMGN) stock popped Wednesday on a solid third-quarter beat as investors focus on what's next for the company's obesity treatment, MariTide. Revenue from cholesterol treatment Repatha surged 40% ...